Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

331
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
331
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

814
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
814
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

704
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
704
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

762
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
762
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

780
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
780

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of PYY, GLP-1 and LEAP2 with changes in feeding-related cognition, body weight and glucose homeostasis after bariatric surgery in non-diabetic women.

Journal of neuroendocrinology·2026
Same author

Oxidative stress index as a potent predictor of disease severity and inflammatory burden in hospitalized COVID-19 patients.

Infectious medicine·2026
Same author

Sclerosing cholangitis and microscopic colitis-In search of the lost cause.

Journal of internal medicine·2026
Same author

Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice-Insights From the AROS Database.

Diabetes, obesity & metabolism·2026
Same author

Types and Outcomes of Dietary Interventions in IBS: A Scoping Review.

Nutrients·2026
Same author

Semaglutide for treatment of intractable diarrhea of different etiologies: a case series of 30 patients.

Scandinavian journal of gastroenterology·2026
Same journal

Assessing trial eligibility and real-world response to vedolizumab and ustekinumab in patients with ulcerative colitis.

Scandinavian journal of gastroenterology·2026
Same journal

M2 macrophage activation in recurrent acute pancreatitis: an explorative analysis of a randomized controlled trial.

Scandinavian journal of gastroenterology·2026
Same journal

Safety and performance of small bowel capsule endoscopy in patients with surgically altered gastrointestinal anatomy.

Scandinavian journal of gastroenterology·2026
Same journal

Textbook outcome after esophagectomy in Norway - a national cohort study of low- to medium-volume centers.

Scandinavian journal of gastroenterology·2026
Same journal

Fecal calprotectin concentration in adults with and without <i>Helicobacter pylori</i> infection.

Scandinavian journal of gastroenterology·2026
Same journal

Endoloop-clip closure versus hemoclips for large sigmoid colon perforations: a randomized controlled <i>ex vivo</i> study.

Scandinavian journal of gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Mar 6, 2026

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.5K

Bariatric surgery - time to replace with GLP-1?

Dominic-Luc Webb1, Niclas Abrahamsson2, Magnus Sundbom3

  • 1a Gastroenterology and Heptatology Unit , Uppsala University , Uppsala , Sweden.

Scandinavian Journal of Gastroenterology
|March 10, 2017
PubMed
Summary
This summary is machine-generated.

Glucagon-like peptide-1 (GLP-1) analogs show promise for obesity treatment, mimicking gastric bypass effects by reducing appetite and promoting weight loss. These therapies offer a lower-risk alternative to surgery for managing obesity and related metabolic issues.

Keywords:
Gastric bypassgastric emptyingglucagon-like peptidesglucose homeostasisweight loss

More Related Videos

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

24.4K
One-anastomosis Gastric Bypass OAGB in Rats
08:16

One-anastomosis Gastric Bypass OAGB in Rats

Published on: November 10, 2018

11.5K

Related Experiment Videos

Last Updated: Mar 6, 2026

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.5K
Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

24.4K
One-anastomosis Gastric Bypass OAGB in Rats
08:16

One-anastomosis Gastric Bypass OAGB in Rats

Published on: November 10, 2018

11.5K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Obesity (BMI > 30 kg/m²) significantly increases morbidity and mortality, reducing life expectancy.
  • Bariatric surgery, particularly gastric bypass, is an effective long-term intervention, altering gut peptide hormone levels.
  • Glucagon-like peptide-1 (GLP-1) is a key gut hormone elevated after gastric bypass, suppressing appetite and food intake.

Purpose of the Study:

  • To explore the therapeutic potential of GLP-1 and its analogs for obesity management.
  • To investigate the role of altered gut hormone profiles in weight loss and glucose homeostasis post-gastric bypass.
  • To evaluate pharmacological interventions targeting GLP-1 pathways as alternatives to bariatric surgery.

Main Methods:

  • Analysis of hormonal changes, specifically GLP-1 levels, following gastric bypass surgery.
  • Review of studies on GLP-1 analogs and dipeptidyl peptidase-IV (DPP-IV) inhibitors for weight loss and metabolic control.
  • Exploration of potential synergistic effects of combining GLP-1 with other gut hormones like PYY and CCK.

Main Results:

  • GLP-1 analogs used for type 2 diabetes treatment also induce significant weight loss.
  • Pharmacological interventions using GLP-1 analogs (e.g., exenatide, liraglutide) and DPP-IV inhibitors (e.g., sitagliptin) reduce appetite and body weight.
  • These interventions demonstrate positive effects on metabolic control, offering a potential link between gut hormones, weight loss, and glucose homeostasis.

Conclusions:

  • GLP-1 has therapeutic potential comparable to gastric bypass for obesity treatment.
  • Pharmacological modulation of the GLP-1 pathway presents a realistic, lower-risk alternative to surgery for obesity-related risk factors.
  • Combinations of GLP-1 with other gut hormones may enhance appetite reduction and food intake control.